Short acting GLP-1 receptor agonist (injectable)
Beinaglutide injection
BEIN_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.95 (-2.06 to 0.22) | 0.57 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.78 (-8.92 to 3.27) | 0.75 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.12 (0.25 to 4.56) | 0.62 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.51 (0.01 to 33.28) | 0.61 |